Delayed systemic therapy after local treatment for lung metastases in colorectal cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the timing of systemic therapy in colorectal cancer patients who have achieved No Evidence of Disease (NED) for at least six months and subsequently develop pulmonary oligometastases. Patients will receive destructive local treatments such as surgery, radiotherapy, or radiofrequency ablation without immediate systemic therapy. The study aims to determine whether delaying systemic treatment is a viable option for these patients, addressing the ongoing debate in multidisciplinary consultations regarding the management of oligometastatic disease. The outcomes will help clarify the best approach to treatment in this specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a pathologically confirmed diagnosis of colorectal cancer with the following disease conditions:

  1. The patient has achieved No Evidence of Disease (NED) after undergoing EMR, surgery, radiofrequency ablation, or radiotherapy.
  2. NED has been maintained for ≥ 6 months.
  3. The patient has not received chemotherapy, or has only received postoperative adjuvant chemotherapy or first-line systemic therapy.
  4. Oligometastatic lung lesions (defined as 5 or fewer lesions) detected after ≥ 6 months of NED maintenance, eligible for destructive therapy.
  5. No prior radiotherapy to the lungs.
* RECIST 1.1 criteria: The patient must have measurable lesions, defined as at least one nodal lesion with a longest diameter \> 1.5 cm, or at least one nodal lesion \> 1 cm with an accurately measurable pendulous diameter.
* ECOG performance status: ≤ 2 (Eastern Cooperative Oncology Group general condition score).
* The patient's expected survival must be ≥ 3 months.
* Adequate hematologic function: Absolute neutrophil count ≥ 1.6 x 10⁹/L, with no growth factor support for at least 7 days prior to testing.
* Normal organ function: The patient must be able to tolerate at least one of the local destructive treatments, as assessed by the corresponding department's physician, based on normal hepatic, renal, pulmonary, and cardiac function.
* Reproductive age: Female patients of childbearing potential must agree to use a reliable method of contraception with their partner from the time of informed consent until 1 year after treatment completion.
* The patient must have voluntarily provided informed consent to participate in the study.

Exclusion Criteria:

* First diagnosis of advanced colorectal cancer with metastatic disease.
* Multiple lung metastases (\> 5 lesions), liver metastasis, bone metastasis, or lymph node metastasis.
* Lung metastases that are not amenable to radiotherapy, as determined by the investigator.
* Previously received second-line or higher systemic treatment.
* Liver or kidney dysfunction: Alanine aminotransferase (ALT) \> 3 times the upper limit of normal; Aspartate aminotransferase (AST) \> 3 times the upper limit of normal; Total bilirubin (TBIL) \> 2 times the upper limit of normal; Serum creatinine \> 1.5 times the upper limit of normal.
* Elevated tumor marker: CEA ≥ 50 ng/mL.
* Serious medical conditions that may interfere with the study (e.g., uncontrolled diabetes, gastric ulcers, severe cardiopulmonary diseases), at the discretion of the researchers.
* Severe or uncontrolled infections.
* Active autoimmune disease.
* Clinically significant central nervous system dysfunction.
* Recent major surgery (excluding lymph node biopsy) within the last 30 days.
* Pregnant or breastfeeding women of childbearing age who are not using contraception.
* Drug allergy to study treatments.
* Other reasons, as determined by the researchers, that make the patient unsuitable for participation.

Where it's running

• Department of Radiation Oncology, Shandong Cancer Hospital and Institute
  Jinan, Shandong, China Recruiting

Study contacts

• Principal investigator: Jinbo Yue, Dorcter — Shandong Cancer Hospital and Institute
• Study coordinator: Jinbo Yue, Dorcter
• Email: jbyue@sdfmu.edu.cn
• Phone: 0531-67626442

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bevacizumab, sintilimab, cetuximab and irinotecan in refractory RAS wild-type metastatic colorectal cancer

  This trial tests whether adding sintilimab to a cetuximab and irinotecan backbone, with or without bevacizumab, helps patients with heavily pretreated metastatic colorectal cancer that has RAS wild-type tumors.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT07722754

• Blood test for early detection of colorectal cancer

  This study is testing a new blood test to see if it can find colorectal cancer early in people with Lynch Syndrome, who are at higher risk for this disease.

  Recruiting Erasmus Medical Center · Leiden, South Holland and 1 other locations · NCT06989814

• Combining irinotecan liposome with chemotherapy for advanced colorectal cancer

  This study is testing a new combination of irinotecan liposome and standard chemotherapy drugs to see if it can help people with advanced colorectal cancer.

  Recruiting Phase 2 Affiliated Hospital of Nantong University · Nanjing, Jiangsu · NCT06643793

• Blood test for early detection of colorectal cancer and adenomas

  This study is testing a new blood test to see if it can help find early signs of colorectal cancer and adenomas in people who are already scheduled for a colonoscopy.

  Recruiting at 6 sites City of Hope Medical Center · Monrovia, California and 5 other locations · NCT06342440

• Detecting early onset colorectal cancer using a blood test

  This study is testing a new blood test that looks for specific markers to help find early signs of colorectal cancer in young adults.

  Recruiting at 13 sites City of Hope Medical Center · Duarte, California and 12 other locations · NCT06342401

• Comparing localized treatment to palliative chemotherapy for colorectal cancer patients with multiple liver metastases

  This study is testing if localized treatments like surgery or radiation can help colorectal cancer patients with multiple liver tumors live longer compared to just using palliative chemotherapy.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT06208371

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.